In contrast to the potential use of oral small-molecule therapy in DCM linked to variants of many sarcomere-expressing genes, more complex treatments such as gene therapy and modified gene processing are required for prevalent DCM disease genes such as the following: (i) variants of TTN, which express the giant protein titin responsible for resting tension and length-dependent signaling, and (ii) variants of LMNA that express lamins that function in nuclear structure control of binding of regulatory elements and chromatin. The gene discussed is LMNA; the disease is familial dilated cardiomyopathy.